This application is for a five-year extension of funding for the Diabetic Retinopathy Clinical Research Network (DRCR.net) Network Chair. The DRCR.net is dedicated to support multicenter clinical research of diabetic retinopathy, macular edema and associated conditions through a collaborative network utilizing specialized infrastructure resources that include a Coordination Center and Network Chair's office. The Network's primary goal is to identify, create, conduct, analyze and report high quality clinical tral protocols that lead to a better understanding of diabetic retinopathy, advance its treatment, and improve the lives of individuals with diabetes. The uniqueness of the Network and its efficiencies of scale allow the performance of protocols using money from the NIH, industry, and foundations. These protocols often involve trials that would not be done by industry and would not be feasible with solely NIH funding. These trials include comparative effectiveness studies, new indications of approved drugs, and the testing of new therapies, including Phase I and II clinical trials. The general goals of the DRCR.net over the next 5 year period include 1) continuing to develop protocols in a rapid and efficient manner while maintaining absolute scientific rigor and integrity, 2) continuously identifying and focusing upcoming studies on the most important medical and public health diabetes ophthalmic issues of the day and 3) continuing the legacy of innovative novel approaches to clinical trial design &implementation, network structure, and education. During the next funding cycle, the Network proposes to complete 6-8 protocols that are expected to be in progress at the time the funding period begins, initiate 10-15 new protocols (including 1-2 new major protocols per year) in diabetic retinopathy, diabetic macular edema and associated conditions, continue to expand the DRCR.net by soliciting the participation of new sites, continue to educate the DRCR.net investigators on the principles of clinical research, and mentor selected retina specialists to be leaders in clinical trials with specific reference to diabetic retinopathy.

Public Health Relevance

The prevalence of diabetes continues to grow in epidemic proportions in the U.S. and the rest of the world. As such, the most feared complication, vision loss from diabetic retinopathy, remains a significant public health problem. The DRCR Network represents a novel approach to facilitating research in this area which already has had a profound effect on the management of diabetic retinopathy, including diabetic macular edema

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10EY023207-01
Application #
8476581
Study Section
Special Emphasis Panel (ZEY1-VSN (05))
Program Officer
Schron, Eleanor
Project Start
2014-02-01
Project End
2018-12-31
Budget Start
2014-02-01
Budget End
2014-12-31
Support Year
1
Fiscal Year
2014
Total Cost
$404,897
Indirect Cost
$92,148
Name
Northwestern University at Chicago
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Gross, Jeffrey G; Glassman, Adam R (2016) A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy. JAMA Ophthalmol 134:13-4
Beaulieu, Wesley T; Bressler, Neil M; Melia, Michele et al. (2016) Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol 170:206-213
Bressler, Susan B; Glassman, Adam R; Almukhtar, Talat et al. (2016) Five-Year Outcomes of Ranibizumab With Prompt or Deferred Laser Versus Laser or Triamcinolone Plus Deferred Ranibizumab for Diabetic Macular Edema. Am J Ophthalmol 164:57-68
Wells, John A; Glassman, Adam R; Jampol, Lee M et al. (2016) Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol 134:127-34
Bressler, Susan B; Melia, Michele; Glassman, Adam R et al. (2015) RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina 35:2516-28
Diabetic Retinopathy Clinical Research Network; Wells, John A; Glassman, Adam R et al. (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372:1193-203
Aiello, Lloyd Paul; Ayala, Allison R; Antoszyk, Andrew N et al. (2015) Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol 133:888-96
Bressler, Susan B; Almukhtar, Talat; Bhorade, Anjali et al. (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589-97
Friedman, Scott M; Almukhtar, Talat H; Baker, Carl W et al. (2015) Topical nepafenec in eyes with noncentral diabetic macular edema. Retina 35:944-56
Elman, Michael J; Ayala, Allison; Bressler, Neil M et al. (2015) Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122:375-81

Showing the most recent 10 out of 34 publications